Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Migraine Disorders: HELP
Articles by Lanfranco Pellesi
Based on 6 articles published since 2008
||||

Between 2008 and 2019, Lanfranco Pellesi wrote the following 6 articles about Migraine Disorders.
 
+ Citations + Abstracts
1 Review Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. 2019

Lupi, Chiara / Benemei, Silvia / Guerzoni, Simona / Pellesi, Lanfranco / Negro, Andrea. ·a Headache Centre, Careggi University Hospital, Health Sciences Department , University of Florence , Florence , Italy. · b Headache Centre, Careggi University Hospital , University of Florence , Florence , Italy. · c Medical Toxicology, Headache and Drug Abuse Center , University of Modena and Reggio Emilia , Modena , Italy. · d Regional Referral Headache Centre, Sant'Andrea Hospital, Department of Clinical and Molecular Medicine , Sapienza University of Rome , Rome , Italy. ·Expert Opin Drug Metab Toxicol · Pubmed #30714429.

ABSTRACT: INTRODUCTION: Recommended medications for the acute treatment of migraine encompass triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and analgesics. While it is true that triptans have been the first successful mechanism-driven treatment in the field, recently, new targets involved in migraine pathogenesis have emerged and new drug classes have been studied for migraine attack therapy. Areas covered: Pharmacodynamics and pharmacokinetics of the new acute treatments of migraine (i.e. ditans, gepants, and glutamate receptor antagonists), considering also marketed drugs in new formulations and administration routes. Expert opinion: Research on the administration routes of marketed drugs was performed in order to improve, in accordance with basic pharmacokinetics parameters, the speed of action of these medications. Similar to the triptans, the new acute treatments are migraine-specific medications, acting on the trigeminovascular system, albeit with different mechanisms. Although available data do not conclusively indicate the superiority of a class over the others, the pharmacodynamics explains the peculiar tolerability and safety profile of different drug classes emerging from clinical trials. Further studies are needed to investigate the possibility of combining different drug classes to optimize the clinical response and the potential role of the novel drugs in medication-overuse headache.

2 Review Migraine and cluster headache - the common link. 2018

Vollesen, Anne Luise / Benemei, Silvia / Cortese, Francesca / Labastida-Ramírez, Alejandro / Marchese, Francesca / Pellesi, Lanfranco / Romoli, Michele / Ashina, Messoud / Lampl, Christian / Anonymous5040974. ·Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. · Health Sciences Department, University of Florence and Headache Centre, Careggi University Hospital, Florence, Italy. · Department of Medico-Surgical Sciences and Biotechnologies, Sapienza, University of Rome, Polo Pontino, Latina, Italy. · Dep Internal Medicine, Division of Vascular Pharmacology, Erasmus Medical Center, Rotterdam, The Netherlands. · Child Neuropsichiatry Unit, University of Palermo, Palermo, Italy. · Medical Toxicology, Headache and Drug Abuse Center, University of Modena and Reggio Emilia, Modena, Italy. · Neurology Clinic, University of Perugia - S.M. Misericordiae Hospital, Perugia, Italy. · Department of Neurogeriatric Medicine, Headache Medical Center Linz, Ordensklinikum Linz Barmherzige Schwestern, Seilerstaette 4, 4010, Linz, Austria. christian.lampl@ordensklinikum.at. ·J Headache Pain · Pubmed #30242519.

ABSTRACT: Although clinically distinguishable, migraine and cluster headache share prominent features such as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine, calcitonin gene-related peptide (CGRP) and response to triptans and neuromodulation. Recent data also suggest efficacy of anti CGRP monoclonal antibodies in both migraine and cluster headache. While exact mechanisms behind both disorders remain to be fully understood, the trigeminovascular system represents one possible common pathophysiological pathway and network of both disorders. Here, we review past and current literature shedding light on similarities and differences in phenotype, heritability, pathophysiology, imaging findings and treatment options of migraine and cluster headache. A continued focus on their shared pathophysiological pathways may be important in paving future treatment avenues that could benefit both migraine and cluster headache patients.

3 Review Triptans and CGRP blockade - impact on the cranial vasculature. 2017

Benemei, Silvia / Cortese, Francesca / Labastida-Ramírez, Alejandro / Marchese, Francesca / Pellesi, Lanfranco / Romoli, Michele / Vollesen, Anne Luise / Lampl, Christian / Ashina, Messoud / Anonymous10660923. ·Health Sciences Department, University of Florence, and Headache Centre, Careggi University Hospital, Viale Pieraccini 6, 50134, Florence, Italy. silvia.benemei@unifi.it. · Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Latina, Italy. · Dept Internal Medicine, Division of Vascular Pharmacology, Erasmus Medical Center, Rotterdam, The Netherlands. · Child Neuropsichiatry Unit, University of Palermo, Palermo, Italy. · Medical Toxicology Headache and Drug Abuse Center, University of Modena and Reggio Emilia, Modena, Italy. · Neurology Clinic, University Hospital of Perugia, Perugia, Italy. · Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medicl Sciences, University of Copenhagen, Copenhagen, Denmark. · Department of Neurogeriatric Medicine, Headache Medical Center Linz, Linz, Austria. · Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ·J Headache Pain · Pubmed #29019093.

ABSTRACT: The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT

4 Review Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. 2017

Pellesi, Lanfranco / Guerzoni, Simona / Pini, Luigi Alberto. ·Medical Toxicology and Headache Center, Policlinic Hospital, University of Modena and Reggio Emilia, Modena, Italy. ·Clin Pharmacol Drug Dev · Pubmed #28409893.

ABSTRACT: Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication-induced (medication-overuse) headache, it is the third-leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up to 40% of migraineurs are eligible for prophylactic treatment, but there are issues of efficacy, safety, and adherence. In recent years the evidence on the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has been consolidated, so new and promising treatments for migraine pain and its possible prevention have been developed. The following review reports the results of the clinical trials conducted so far with each of the new monoclonal antibodies targeting CGRP or its receptor, with particular reference to safety, tolerance, and efficacy in migraine prevention. Moreover, the pharmacological characterization and further developments of each monoclonal antibody are reported, based on current knowledge.

5 Article Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. 2019

Sacco, Simona / Benemei, Silvia / Cevoli, Sabina / Coppola, Gianluca / Cortelli, Pietro / De Cesaris, Francesco / De Icco, Roberto / De Marco, Cristiano Maria / Di Lorenzo, Cherubino / Geppetti, Pierangelo / Manni, Alessia / Negro, Andrea / Ornello, Raffaele / Pierangeli, Giulia / Pierelli, Francesco / Pellesi, Lanfranco / Pini, Luigi Alberto / Pistoia, Francesca / Prudenzano, Maria Pia / Russo, Antonio / Sances, Grazia / Taranta, Valentina / Tassorelli, Cristina / Tedeschi, Gioacchino / Trojano, Maria / Martelletti, Paolo. ·Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L'Aquila, L'Aquila, Italy. simona.sacco@univaq.it. · Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy. · IRCCS Institute of Neurological Science of Bologna, Bologna, Italy. · Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University Polo Pontino, Latina, Italy. · Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. · Headache Science Center, IRCCS C. Mondino Foundation, Pavia, Italy. · Department of Clinical and Molecular Medicine, Regional Referral Headache Centre, Sant'Andrea Hospital, Sapienza University, Rome, Italy. · Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy. · Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L'Aquila, L'Aquila, Italy. · IRCCS NEUROMED, Pozzilli, IS, Italy. · Headache and Drug Abuse Research Centre, Policlinico Hospital, University of Modena e Reggio Emilia, Modena, Italy. · Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Caserta, Italy. · Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. ·J Headache Pain · Pubmed #30760199.

ABSTRACT: BACKGROUND: Case-finding tools, such as the Identify Chronic Migraine (ID-CM) questionnaire, can improve detection of CM and alleviate its significant societal burden. We aimed to develop and validate the Italian version of the ID-CM (ID-EC) in paper and as a smart app version in a headache clinic-based setting. METHODS: The study investigators translated and adapted to the Italian language the original ID-CM questionnaire (ID-EC) and further implemented it as a smart app. The ID-EC was tested in its paper and electronic version in consecutive patients referring to 9 Italian tertiary headache centers for their first in-person visit. The scoring algorithm of the ID-EC paper version was applied by the study investigators (case-finding) and by patients (self-diagnosis), while the smart app provided to patients automatically the diagnosis. Diagnostic accuracy of the ID-EC was assessed by matching the questionnaire results with the interview-based diagnoses performed by the headache specialists during the visit according to the criteria of International Classification of Headache Disorders, III edition, beta version. RESULTS: We enrolled 531 patients in the test of the paper version of ID-EC and 427 in the validation study of the smart app. According to the clinical diagnosis 209 patients had CM in the paper version study and 202 had CM in the smart app study. 79.5% of patients returned valid paper questionnaires, while 100% of patients returned valid and complete smart app questionnaires. The paper questionnaire had a 81.5% sensitivity and a 81.1% specificity for case-finding and a 30.7% sensitivity and 90.7% specificity for self-diagnosis, while the smart app had a 64.9% sensitivity and 90.2% specificity. CONCLUSIONS: Our data suggest that the ID-EC, developed and validated in tertiary headache centers, is a valid case-finding tool for CM, with sensitivity and specificity values above 80% in paper form, while the ID-EC smart app is more useful to exclude CM diagnosis in case of a negative result. Further studies are warranted to assess the diagnostic accuracy of the ID-EC in general practice and population-based settings.

6 Article Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. 2015

Guerzoni, Simona / Pellesi, Lanfranco / Baraldi, Carlo / Pini, Luigi Alberto. ·Headache and Drug Abuse Research Centre, Policlinico Hospital, University of Modena e Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy. simona_guerzoni@libero.it. · Headache and Drug Abuse Research Centre, Policlinico Hospital, University of Modena e Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy. ·J Headache Pain · Pubmed #27146068.

ABSTRACT: BACKGROUND: Chronic migraine is one of the most common diseases in the world and it is often associated with medication overuse that can worsen the headache itself. Thus, it is important to adopt effective therapies to relieve pain and improve patients' quality of life. The PREEMT studies have already demonstrated the effectiveness of OnabotulinumtoxinA in the treatment of chronic migraine. With this in mind, the aim of this real life observation has been to assess the clinical improvements as well as the impact on the quality of life of patients being regularly (every three months) administered this therapy. METHODS: Data from 66 chronic-migraineurs treated with OnabotulinumtoxinA after failing previous therapies were collected. Only 57 of them were analysed since 9 discontinued the therapy due to administrative reasons. For every patient enrolled, headache frequency, analgesic consumption, pain severity, headache-related disability, health-related quality of life as well as anxiety and depression symptoms were collected through the Headache Index (HI), analgesic consumption rate in one day (AC), VAS score, Headache Impact Test (HIT-6) and the Short Form (36) Health Survey questionnaire Version 2 (SF-36®), Zung Self-Rating Anxiety Scale (ZUNG-A) and Zung Self-Rating Depression Scale (ZUNG-D), respectively. All the changes vs baseline (Tx vs T0) were expressed as mean ± SD and analysed with a one-way ANOVA plus non-parametric Wilcoxon test, that was used for paired data for each subject. RESULTS: As the number of injection increased, those patients injected regularly observed a statistically significant reduction in the headache frequency, pain intensity, headache disability score and an overall marked improvement in patients' quality of life. There was also a significant reduction in anxiety and depressive symptoms as for the ZUNG-A and ZUNG-D scales scores. At any time point, those patients who stopped the therapy worsened their overall conditions as confirmed by quality of life parameters. CONCLUSIONS: This study outpoints that OnabotulinumtoxinA treatment is an effective treatment to reduce the headache-related disability and improve patients' quality of life when patients are treated regularly every three months and consistently overtime. Therapy discontinuation leads to a general worsening of health-related quality of life. Long term treatment over one year confirms a consistently positive and sustained trend of improvement with a high safety profile.